One more dysplasia

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Gastric epithelial dysplasia is the earliest visible stage of neoplasia. Most histopathologists can recognize or at least suspect it, and a set of established clinical responses follow its detection. In contrast, proliferations and dysplastic changes of gastric endocrine cells are difficult to identify and generally neglected. Such changes are known to predispose to the development of carcinoid tumours and usually arise in patients with corpus-predominant atrophic gastritis and elevated gastrin levels. A report in this issue suggests that patients with dysplasia of the enterochromaffin-like cells have a much greater risk of developing carcinoid tumours than previously suspected. These carcinoids (known as type I) tend to have an indolent course, are almost never functional and have a favourable prognosis; nevertheless, they need to be detected and excised endoscopically. Because of the small numbers of patients in this series and the relatively short follow-up time of the study, it would be premature to issue guidelines on the long-term management of patients with atrophic gastritis and hypergastrinaemia. However, it is incumbent on clinical researchers with access to well-defined cohorts, such as the one studied here, to continue the follow-up studies that will lead to a more precise definition of risk and to the development of usable evidence-based clinical strategies.

Original languageEnglish (US)
Pages (from-to)1411-1414
Number of pages4
JournalEuropean Journal of Gastroenterology and Hepatology
Volume13
Issue number12
DOIs
StatePublished - 2001

Fingerprint

Carcinoid Tumor
Atrophic Gastritis
Stomach
Enterochromaffin-like Cells
Time and Motion Studies
Endocrine Cells
Gastrins
Research Personnel
Guidelines
Neoplasms

Keywords

  • Atrophic gastritis
  • Atrophy
  • Dysplasia
  • Gastritis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

One more dysplasia. / Genta, Robert M.

In: European Journal of Gastroenterology and Hepatology, Vol. 13, No. 12, 2001, p. 1411-1414.

Research output: Contribution to journalArticle

@article{4fd7c2a6290c4bd797876e240827803e,
title = "One more dysplasia",
abstract = "Gastric epithelial dysplasia is the earliest visible stage of neoplasia. Most histopathologists can recognize or at least suspect it, and a set of established clinical responses follow its detection. In contrast, proliferations and dysplastic changes of gastric endocrine cells are difficult to identify and generally neglected. Such changes are known to predispose to the development of carcinoid tumours and usually arise in patients with corpus-predominant atrophic gastritis and elevated gastrin levels. A report in this issue suggests that patients with dysplasia of the enterochromaffin-like cells have a much greater risk of developing carcinoid tumours than previously suspected. These carcinoids (known as type I) tend to have an indolent course, are almost never functional and have a favourable prognosis; nevertheless, they need to be detected and excised endoscopically. Because of the small numbers of patients in this series and the relatively short follow-up time of the study, it would be premature to issue guidelines on the long-term management of patients with atrophic gastritis and hypergastrinaemia. However, it is incumbent on clinical researchers with access to well-defined cohorts, such as the one studied here, to continue the follow-up studies that will lead to a more precise definition of risk and to the development of usable evidence-based clinical strategies.",
keywords = "Atrophic gastritis, Atrophy, Dysplasia, Gastritis",
author = "Genta, {Robert M.}",
year = "2001",
doi = "10.1097/00042737-200112000-00003",
language = "English (US)",
volume = "13",
pages = "1411--1414",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - One more dysplasia

AU - Genta, Robert M.

PY - 2001

Y1 - 2001

N2 - Gastric epithelial dysplasia is the earliest visible stage of neoplasia. Most histopathologists can recognize or at least suspect it, and a set of established clinical responses follow its detection. In contrast, proliferations and dysplastic changes of gastric endocrine cells are difficult to identify and generally neglected. Such changes are known to predispose to the development of carcinoid tumours and usually arise in patients with corpus-predominant atrophic gastritis and elevated gastrin levels. A report in this issue suggests that patients with dysplasia of the enterochromaffin-like cells have a much greater risk of developing carcinoid tumours than previously suspected. These carcinoids (known as type I) tend to have an indolent course, are almost never functional and have a favourable prognosis; nevertheless, they need to be detected and excised endoscopically. Because of the small numbers of patients in this series and the relatively short follow-up time of the study, it would be premature to issue guidelines on the long-term management of patients with atrophic gastritis and hypergastrinaemia. However, it is incumbent on clinical researchers with access to well-defined cohorts, such as the one studied here, to continue the follow-up studies that will lead to a more precise definition of risk and to the development of usable evidence-based clinical strategies.

AB - Gastric epithelial dysplasia is the earliest visible stage of neoplasia. Most histopathologists can recognize or at least suspect it, and a set of established clinical responses follow its detection. In contrast, proliferations and dysplastic changes of gastric endocrine cells are difficult to identify and generally neglected. Such changes are known to predispose to the development of carcinoid tumours and usually arise in patients with corpus-predominant atrophic gastritis and elevated gastrin levels. A report in this issue suggests that patients with dysplasia of the enterochromaffin-like cells have a much greater risk of developing carcinoid tumours than previously suspected. These carcinoids (known as type I) tend to have an indolent course, are almost never functional and have a favourable prognosis; nevertheless, they need to be detected and excised endoscopically. Because of the small numbers of patients in this series and the relatively short follow-up time of the study, it would be premature to issue guidelines on the long-term management of patients with atrophic gastritis and hypergastrinaemia. However, it is incumbent on clinical researchers with access to well-defined cohorts, such as the one studied here, to continue the follow-up studies that will lead to a more precise definition of risk and to the development of usable evidence-based clinical strategies.

KW - Atrophic gastritis

KW - Atrophy

KW - Dysplasia

KW - Gastritis

UR - http://www.scopus.com/inward/record.url?scp=0035216204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035216204&partnerID=8YFLogxK

U2 - 10.1097/00042737-200112000-00003

DO - 10.1097/00042737-200112000-00003

M3 - Article

VL - 13

SP - 1411

EP - 1414

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 12

ER -